July 2022—EKF Diagnostics announced the availability of the FDA-cleared Lucica Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corp. and sold exclusively in the United States by EKF.
Lucica Glycated Albumin-L is a specific, quantitative test for glycated albumin for the intermediate-term monitoring of glycemic control in patients with diabetes. It is an enzymatic method for use on compatible clinical chemistry analyzers that have open channel capability. Glycated albumin and total albumin are determined in separate reactions and results are expressed as a ratio (percent). The test is also standardized to an established reference material.
EKF is exhibiting its range of laboratory and point-of-care diagnostics products at the AACC Clinical Lab Expo in Chicago, July 26–28, including its newly launched EKF Link middleware. The downloadable software package offers secure management of point-of-care analyzers and associated data on a centralized platform. It is an open and flexible solution that can be interfaced to all POC analyzers to enable real-time remote management of data, including patient test results, QC results, operator management, and analyzer configuration, and can integrate patient test results with a laboratory or hospital information system.
EKF Diagnostics, 830-249-0772